SLC5A2 and heart failure: According to the 2022 guidelines of the American Heart Association, American College of Cardiology, and Heart Failure Society of America, SGLT-2 inhibitors have been designated as Class I, level A drugs for the management of heart failure with reduced ejection fraction and as Class II A, level B for treating heart failure with mildly reduced ejection fraction (HFmEF; EF-41-49%) or preserved EF (HFpEF; LVEF-50%) [8].